Ascent Scientific launches first commercial source of YM 202074 - to help research into stroke
October 06, 2009 (PRLEAP.COM) Health NewsAscent Scientific (www.ascentscientific.com) announced the availability of the first commercial source of YM 202074 - a new research tool that will aid research into stroke. YM 202074 is the latest addition to the Low-Cost Ligand range. It acts as a potent, selective allosteric antagonist at the mGlu1 glutamate receptor.
Steve Roome PhD, Commercial Director commented, "Ascent Scientific is proud to be the first life science supplier to make this research tool commercially available to the scientific community.
We continue to excel at making science affordable whilst offering the most up-to-date tools to researchers. The Low-Cost Ligand range already includes VU0155041, cis-PPDA and AMN082 - all cutting-edge tools that Ascent Scientific offered to scientists before any other life science vendor."
YM 202074 is available at very high purity (at least 98%) in 10 mg and 50 mg pack sizes.
Contact: Steve Roome, Commercial Director +44 (0)117 982 99 88 email@example.com
About Ascent Scientific
Ascent Scientific offers a range of high quality receptor ligands and synthetic chemistry services at prices so low that as many researchers as possible will be able to afford them.
The Low-Cost Ligand range includes receptor ligands and signalling tools in research areas such as glutamate, GABA, ion channels, cannabinoids, opioids, 5-HT and more.
The Low-Cost Chemistry Service provides cost-effective custom synthesis of organic molecules, fluorescent labels, standards & references, stable isotope labels, receptor ligands and more.
Ascent Scientific operates out of UK headquarters in Bristol, and a US Sales & Distribution office in New Jersey.
To request a new catalogue, visit our website www.ascentscientific.com, or contact customer service at firstname.lastname@example.org.